Takao Kanzaki1,2, Tetsuya Higuchi3, Yasuyuki Takahashi2, Takayuki Suto1, Yoshito Tsushima3. 1. Department of Radiology, Gunma University Hospital, Gunma, Japan. 2. Department of Nuclear Medicine Technology, Hirosaki University Graduate School of Health Sciences, Hirosaki, Japan. 3. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Gunma, Japan.
Abstract
OBJECTIVES: I-123-ioflupane single photon emission computed tomography (FP-CIT-SPECT) has been used to assess dopamine transporter (DAT) loss in Parkinson's disease. The specific binding ratio (SBR), a quantitative parameter of DAT density in the striatum, may be affected by differences in age, sex, and SPECT system. The purpose of this study was to evaluate the utility of FP-CIT-SPECT using the Japanese normal database (NDB) in the diagnosis of Parkinson's disease. METHODS: To standardize the quantitative outcome measures of DAT density obtained with different SPECT systems, striatal phantoms filled with striatal to background materials at ratios between 8:1 and 1:1 were measured using a gamma camera (ECAM) in our institute. Consecutive fifty patients (23 men and 27 women; age range, 40-86 years) with suspected PD undergoing FP-CIT SPECT brain imaging during the period from April to October 2016 were enrolled in this retrospective study. Their final diagnoses were PD in 28 patients and PD in 22 patients. SBRs of the patients were calculated using either new (Japanese database with different age and sex; NEWver) or old (non-Japanese database not specifying age and sex; OLDver) version software (AZE Virtual Place Hayabusa [DaTView], AZE, Ltd. Tokyo, Japan). The McNemar test was used to compare the diagnostic accuracy between old and new versions. RESULTS: Based on the phantom study, the calibrated SBR could be calculated by Y=1.25×Measured SBR+0.78. The sensitivities for OLDver and NEWver were 100% and 93%, respectively (p=0.5), and the specificities were 55% and 100% (p=0.002). The diagnostic accuracy of NEWver (96%) was better than that of OLDver (80%, p<0.001). CONCLUSION: FP-CIT-SPECT using the Japanese NDB improved the diagnostic accuracy of PD by improving specificity.
OBJECTIVES: I-123-ioflupane single photon emission computed tomography (FP-CIT-SPECT) has been used to assess dopamine transporter (DAT) loss in Parkinson's disease. The specific binding ratio (SBR), a quantitative parameter of DAT density in the striatum, may be affected by differences in age, sex, and SPECT system. The purpose of this study was to evaluate the utility of FP-CIT-SPECT using the Japanese normal database (NDB) in the diagnosis of Parkinson's disease. METHODS: To standardize the quantitative outcome measures of DAT density obtained with different SPECT systems, striatal phantoms filled with striatal to background materials at ratios between 8:1 and 1:1 were measured using a gamma camera (ECAM) in our institute. Consecutive fifty patients (23 men and 27 women; age range, 40-86 years) with suspected PD undergoing FP-CIT SPECT brain imaging during the period from April to October 2016 were enrolled in this retrospective study. Their final diagnoses were PD in 28 patients and PD in 22 patients. SBRs of the patients were calculated using either new (Japanese database with different age and sex; NEWver) or old (non-Japanese database not specifying age and sex; OLDver) version software (AZE Virtual Place Hayabusa [DaTView], AZE, Ltd. Tokyo, Japan). The McNemar test was used to compare the diagnostic accuracy between old and new versions. RESULTS: Based on the phantom study, the calibrated SBR could be calculated by Y=1.25×Measured SBR+0.78. The sensitivities for OLDver and NEWver were 100% and 93%, respectively (p=0.5), and the specificities were 55% and 100% (p=0.002). The diagnostic accuracy of NEWver (96%) was better than that of OLDver (80%, p<0.001). CONCLUSION: FP-CIT-SPECT using the Japanese NDB improved the diagnostic accuracy of PD by improving specificity.
Authors: Livia Tossici-Bolt; John C Dickson; Terez Sera; Robin de Nijs; Maria Claudia Bagnara; Catherine Jonsson; Egon Scheepers; Felicia Zito; Anita Seese; Pierre Malick Koulibaly; Ozlem L Kapucu; Michel Koole; Maria Raith; Jean George; Markus Nowak Lonsdale; Wolfgang Münzing; Klaus Tatsch; Andrea Varrone Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-06 Impact factor: 9.236
Authors: Hani T S Benamer; Jim Patterson; Donald G Grosset; J Booij; K de Bruin; E van Royen; J D Speelman; M H I M Horstink; H J W A Sips; R A Dierckx; J Versijpt; D Decoo; C Van Der Linden; D M Hadley; M Doder; A J Lees; D C Costa; S Gacinovic; W H Oertel; O Pogarell; H Hoeffken; K Joseph; K Tatsch; J Schwarz; V Ries Journal: Mov Disord Date: 2000-05 Impact factor: 10.338
Authors: Aki Laakso; Harry Vilkman; J Bergman; Merja Haaparanta; Olof Solin; Erkka Syvälahti; Raimo K R Salokangas; Jarmo Hietala Journal: Biol Psychiatry Date: 2002-10-01 Impact factor: 13.382
Authors: Livia Tossici-Bolt; Sandra M A Hoffmann; Paul M Kemp; Rajnikant L Mehta; John S Fleming Journal: Eur J Nucl Med Mol Imaging Date: 2006-07-21 Impact factor: 10.057
Authors: Livia Tossici-Bolt; John C Dickson; Terez Sera; Jan Booij; Susanne Asenbaun-Nan; Maria C Bagnara; Thierry Vander Borght; Cathrine Jonsson; Robin de Nijs; Swen Hesse; Pierre M Koulibaly; Umit O Akdemir; Michel Koole; Klaus Tatsch; Andrea Varrone Journal: EJNMMI Phys Date: 2017-01-28
Authors: John T O'Brien; Wolfgang H Oertel; Ian G McKeith; Donald G Grosset; Zuzana Walker; Klaus Tatsch; Eduardo Tolosa; Paul F Sherwin; Igor D Grachev Journal: BMJ Open Date: 2014-07-03 Impact factor: 2.692